FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984567379> ?p ?o ?g. }

• W1984567379 endingPage "988.e1" @default.
• W1984567379 startingPage "980" @default.
• W1984567379 abstract "Background & AimsTenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited.MethodsIn a prospective, double-blind, 96-week trial, patients were randomly assigned (1:1) to groups given TDF (300 mg, n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF). Patients were hepatitis B e antigen (HBeAg)−positive or HBeAg-negative, with levels of HBV DNA ≥3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or reverse transcriptase amino acid substitutions rtM204I/V ± rtL180M by INNO-LiPA Multi-DR v3; Innogenetics, Inc, Alpharetta, GA). The primary end point was proportion with HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc, Pleasanton, CA).ResultsPatient groups were well matched for demographic and disease characteristics, including region (60% from Europe), HBV genotype (45% genotype D), HBeAg status (47% HBeAg-positive), and duration of lamivudine treatment (mean, 3.8 years). At week 96 of treatment, 89.4% of patients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43). HBeAg loss and seroconversion did not differ between groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen. Treatment was well tolerated; confirmed renal events (creatinine increase of ≥0.5 mg/dL [>44 umol/L], creatinine clearance <50 mL/min, or level of PO4 <2 mg/dL [<0.65 mmol/L]) were generally mild and infrequent (<1%). Small reductions (<2%) in mean bone mineral density of hip and spine were detected by dual-energy x-ray absorptiometry in both groups. No TDF resistance developed through 96 weeks of treatment.ConclusionsTDF alone is safe and effective for treatment of patients with lamivudine-resistant, chronic HBV infection. Clinical Trials.gov No, NCT00737568. Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited. In a prospective, double-blind, 96-week trial, patients were randomly assigned (1:1) to groups given TDF (300 mg, n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF). Patients were hepatitis B e antigen (HBeAg)−positive or HBeAg-negative, with levels of HBV DNA ≥3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or reverse transcriptase amino acid substitutions rtM204I/V ± rtL180M by INNO-LiPA Multi-DR v3; Innogenetics, Inc, Alpharetta, GA). The primary end point was proportion with HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc, Pleasanton, CA). Patient groups were well matched for demographic and disease characteristics, including region (60% from Europe), HBV genotype (45% genotype D), HBeAg status (47% HBeAg-positive), and duration of lamivudine treatment (mean, 3.8 years). At week 96 of treatment, 89.4% of patients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43). HBeAg loss and seroconversion did not differ between groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen. Treatment was well tolerated; confirmed renal events (creatinine increase of ≥0.5 mg/dL [>44 umol/L], creatinine clearance <50 mL/min, or level of PO4 <2 mg/dL [<0.65 mmol/L]) were generally mild and infrequent (<1%). Small reductions (<2%) in mean bone mineral density of hip and spine were detected by dual-energy x-ray absorptiometry in both groups. No TDF resistance developed through 96 weeks of treatment. TDF alone is safe and effective for treatment of patients with lamivudine-resistant, chronic HBV infection. Clinical Trials.gov No, NCT00737568." @default.
• W1984567379 created "2016-06-24" @default.
• W1984567379 creator A5009805812 @default.
• W1984567379 creator A5012052658 @default.
• W1984567379 creator A5013093899 @default.
• W1984567379 creator A5015332236 @default.
• W1984567379 creator A5019634418 @default.
• W1984567379 creator A5023275678 @default.
• W1984567379 creator A5030460373 @default.
• W1984567379 creator A5050079986 @default.
• W1984567379 creator A5052510325 @default.
• W1984567379 creator A5064179616 @default.
• W1984567379 creator A5065724405 @default.
• W1984567379 creator A5066314767 @default.
• W1984567379 creator A5078642431 @default.
• W1984567379 creator A5085805700 @default.
• W1984567379 creator A5088683463 @default.
• W1984567379 creator A5088842832 @default.
• W1984567379 date "2014-04-01" @default.
• W1984567379 modified "2023-10-15" @default.
• W1984567379 title "Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B" @default.
• W1984567379 cites W1976104517 @default.
• W1984567379 cites W1976162727 @default.
• W1984567379 cites W1977682488 @default.
• W1984567379 cites W1993605600 @default.
• W1984567379 cites W2004054613 @default.
• W1984567379 cites W2009509017 @default.
• W1984567379 cites W2012138074 @default.
• W1984567379 cites W2014279976 @default.
• W1984567379 cites W2014837723 @default.
• W1984567379 cites W2016449892 @default.
• W1984567379 cites W2031317669 @default.
• W1984567379 cites W2033980504 @default.
• W1984567379 cites W2037314166 @default.
• W1984567379 cites W2051976356 @default.
• W1984567379 cites W2056779298 @default.
• W1984567379 cites W2059560167 @default.
• W1984567379 cites W2073197508 @default.
• W1984567379 cites W2088280741 @default.
• W1984567379 cites W2089922577 @default.
• W1984567379 cites W2090738619 @default.
• W1984567379 cites W2095855829 @default.
• W1984567379 cites W2102770845 @default.
• W1984567379 cites W2107552769 @default.
• W1984567379 cites W2117947644 @default.
• W1984567379 cites W2134595040 @default.
• W1984567379 cites W2137544368 @default.
• W1984567379 cites W2143584498 @default.
• W1984567379 cites W2144095981 @default.
• W1984567379 cites W2147133758 @default.
• W1984567379 cites W2159388918 @default.
• W1984567379 cites W2163577777 @default.
• W1984567379 cites W2943463865 @default.
• W1984567379 cites W4211026375 @default.
• W1984567379 cites W93400950 @default.
• W1984567379 doi "https://doi.org/10.1053/j.gastro.2013.12.028" @default.
• W1984567379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24368224" @default.
• W1984567379 hasPublicationYear "2014" @default.
• W1984567379 type Work @default.
• W1984567379 sameAs 1984567379 @default.
• W1984567379 citedByCount "144" @default.
• W1984567379 countsByYear W19845673792014 @default.
• W1984567379 countsByYear W19845673792015 @default.
• W1984567379 countsByYear W19845673792016 @default.
• W1984567379 countsByYear W19845673792017 @default.
• W1984567379 countsByYear W19845673792018 @default.
• W1984567379 countsByYear W19845673792019 @default.
• W1984567379 countsByYear W19845673792020 @default.
• W1984567379 countsByYear W19845673792021 @default.
• W1984567379 countsByYear W19845673792022 @default.
• W1984567379 countsByYear W19845673792023 @default.
• W1984567379 crossrefType "journal-article" @default.
• W1984567379 hasAuthorship W1984567379A5009805812 @default.
• W1984567379 hasAuthorship W1984567379A5012052658 @default.
• W1984567379 hasAuthorship W1984567379A5013093899 @default.
• W1984567379 hasAuthorship W1984567379A5015332236 @default.
• W1984567379 hasAuthorship W1984567379A5019634418 @default.
• W1984567379 hasAuthorship W1984567379A5023275678 @default.
• W1984567379 hasAuthorship W1984567379A5030460373 @default.
• W1984567379 hasAuthorship W1984567379A5050079986 @default.
• W1984567379 hasAuthorship W1984567379A5052510325 @default.
• W1984567379 hasAuthorship W1984567379A5064179616 @default.
• W1984567379 hasAuthorship W1984567379A5065724405 @default.
• W1984567379 hasAuthorship W1984567379A5066314767 @default.
• W1984567379 hasAuthorship W1984567379A5078642431 @default.
• W1984567379 hasAuthorship W1984567379A5085805700 @default.
• W1984567379 hasAuthorship W1984567379A5088683463 @default.
• W1984567379 hasAuthorship W1984567379A5088842832 @default.
• W1984567379 hasConcept C126322002 @default.
• W1984567379 hasConcept C159047783 @default.
• W1984567379 hasConcept C2522874641 @default.
• W1984567379 hasConcept C2775940106 @default.
• W1984567379 hasConcept C2776175608 @default.
• W1984567379 hasConcept C2777382497 @default.
• W1984567379 hasConcept C2777410769 @default.
• W1984567379 hasConcept C2777869810 @default.
• W1984567379 hasConcept C2779778239 @default.
• W1984567379 hasConcept C2780593183 @default.

• next